Natriuretic peptides buffer renin-dependent hypertension.
The renin-angiotensin-aldosterone system and cardiac natriuretic peptides [atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP)] are opposing control mechanisms for arterial blood pressure. Accordingly, an inverse relationship between plasma renin concentration (PRC) and ANP exists in most circumstances. However, PRC and ANP levels are both elevated in renovascular hypertension. Because ANP can directly suppress renin release, we used ANP knockout (ANP(-/-)) mice to investigate whether high ANP levels attenuate the increase in PRC in response to renal hypoperfusion, thus buffering renovascular hypertension. ANP(-/-) mice were hypertensive and had reduced PRC compared with that in wild-type ANP(+/+) mice under control conditions. Unilateral renal artery stenosis (2-kidney, 1-clip) for 1 wk induced similar increases in blood pressure and PRC in both genotypes. Unexpectedly, plasma BNP concentrations in ANP(-/-) mice significantly increased in response to two-kidney, one-clip treatment, potentially compensating for the lack of ANP. In fact, in mice lacking guanylyl cyclase A (GC-A(-/-) mice), which is the common receptor for both ANP and BNP, renovascular hypertension was markedly augmented compared with that in wild-type GC-A(+/+) mice. However, the higher blood pressure in GC-A(-/-) mice was not caused by disinhibition of the renin system because PRC and renal renin synthesis were significantly lower in GC-A(-/-) mice than in GC-A(+/+) mice. Thus, natriuretic peptides buffer renal vascular hypertension via renin-independent effects, such as vasorelaxation. The latter possibility is supported by experiments in isolated perfused mouse kidneys, in which physiological concentrations of ANP and BNP elicited renal vasodilatation and attenuated renal vasoconstriction in response to angiotensin II.
Institute of Physiology, University of Regensburg, Regensburg, Germany.
Theo
T
Demerath
Institute of Physiology, University of Regensburg, Regensburg, Germany.
Janina
J
Staffel
Institute of Physiology, University of Regensburg, Regensburg, Germany.
Andrea
A
Schreiber
Institute of Physiology, University of Regensburg, Regensburg, Germany.
Daniela
D
Valletta
Institute of Physiology, University of Regensburg, Regensburg, Germany frank.schweda@klinik.uni-regensburg.de.
Frank
F
Schweda
D000818:Animals; D009320:Atrial Natriuretic Factor / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D001794:Blood Pressure / Q000502:physiology; D004195:Disease Models, Animal; D006978:Hypertension, Renovascular / Q000378:metabolism* / Q000503:physiopathology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D020097:Natriuretic Peptide, Brain / Q000378:metabolism*; D017461:Receptors, Atrial Natriuretic Factor / Q000172:deficiency / Q000235:genetics / Q000378:metabolism; D012083:Renin / Q000378:metabolism*; D012084:Renin-Angiotensin System / Q000502:physiology; D013525:Surgical Instruments; D014661:Vasoconstriction / Q000502:physiology; D014664:Vasodilation / Q000502:physiology
D020097:Natriuretic Peptide, Brain; D009320:Atrial Natriuretic Factor; D012083:Renin; D017461:Receptors, Atrial Natriuretic Factor; C091715:atrial natriuretic factor receptor A
B-type natriuretic peptide; atrial natriuretic peptide; guanylyl cyclase A; hypertension; renin